Thousand Oaks, CA. FUJIFILM Diosynth Biotechnologies, a subsidiary of FUJIFILM Corporation, is a world-leading contract development and manufacturing organization (CDMO) with experience in the development and manufacture of biologics, vaccines and advanced therapies. Healthcare Providers, https://www.businesswire.com/news/home/20220126006000/en/. This press release contains or may imply forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. The parties will also enter a long-term supply agreement, which could extend to ten years. HCRx is a leading royalty acquisition company focused on commercial or near . FUJIFILM Holdings America Corporation These products and services are based on its extensive portfolio of chemical, mechanical, optical, electronic and imaging technologies. Suite 102 Read our related press release: FUJIFILM Diosynth Biotechnologies and RoosterBio Announce Collaboration to enable GMP Manufacturing of Cell and Exosome Therapies, 3939 Fujifilm Way About FUJIFILM Diosynth Biotechnologies Atara is applying this one platform, which does not require TCR or HLA gene editing, to create a robust pipeline including: tab-cel in Phase 3 development for Epstein-Barr virus-driven post-transplant lymphoproliferative disease (EBV+ PTLD) and other EBV-driven diseases; ATA188, a T-cell immunotherapy targeting EBV antigens as a potential treatment for multiple sclerosis; and multiple next-generation chimeric antigen receptor T-cell (CAR-T) immunotherapies for both solid tumors and hematologic malignancies. Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced FUJIFILM Diosynth Biotechnologies, a subsidiary of FUJIFILM Corporation (Fujifilm), has completed the acquisition of Ataras cell therapy manufacturing facility in Thousand Oaks, California for USD 100 million upfront and the commencement of a long-term strategic supply agreement. 805-456-4772 This information is preliminary, has not been audited, and is subject to change upon the audit of the companys financial statements for the year ended December 31, 2021. We believe that now is the right time for a strategic relationship with FUJIFILM Diosynth Biotechnologies to give us access to the expert manufacturing capability Atara will require, when needed. For the year ended March 31, 2021, the company had global revenues of $21 billion, at an exchange rate of 106 yen to the dollar. A live audio webcast can be accessed by visiting the Investors & Media News & Events section of www.atarabio.com. Sie knnen Ihre Einstellungen jederzeit ndern, indem Sie auf unseren Websites und Apps auf den Link Datenschutz-Dashboard klicken. INVESTORS & MEDIA: Fujifilm is committed to responsible environmental stewardship and good corporate citizenship. FUJIFILM Diosynth Biotechnologies California, Inc. entered into an asset purchase agreement to acquire T-Cell Operations and Manufacturing Facility in Thousand Oaks, California from Atara Biotherapeutics, Inc. (NasdaqGS:ATRA) for $100 million on January 26, 2022. The company offers a comprehensive list of services from cell line development using its proprietary pAVEway microbial and ApolloX cell line systems to process development, analytical development, clinical and FDA-approved commercial manufacturing. This partnership and acquisition was first announced in January 2022. Atara Biotherapeutics, Inc. . The company offers a comprehensive list of services from cell line development using its proprietary pAVEway microbial and ApolloX cell line systems to process development, analytical development, clinical and FDA-approved commercial manufacturing. FUJIFILM Diosynth Biotechnologies will also expand use of the Thousand Oaks site to manufacture a broader portfolio of cell therapies by leveraging the experience and expertise of the manufacturing and quality staff who transitioned to FUJIFILM Diosynth Biotechnologies. Fujifilm Completes Acquisition of a Dedicated Cell Therapy Manufacturing Facility from Atara Biotherapeutics, Inc. United States of America Investors SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Atara Biotherapeutics, Inc., (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced FUJIFILM Diosynth Biotechnologies, a subsidiary of FUJIFILM Corporation (Fujifilm), has completed the acquisition of . FUJIFILM Corporation will continue to expand its bio CDMO business by leveraging its strength of being able to handle a wide variety of biopharmaceutical process development and manufacturing from clinical to commercial scale for drug products, fill & finish, and packaging. SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Atara Biotherapeutics, Inc.,(Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced FUJIFILM Diosynth Biotechnologies, a subsidiary of FUJIFILM Corporation (Fujifilm), has completed the acquisition of Ataras cell therapy manufacturing facility in Thousand Oaks, California for USD 100 million upfront and the commencement of a long-term strategic supply agreement. +1 617 798 5211. The closing of the transaction, subject to expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act and other customary closing conditions, is expected to occur in April 2022. Our platform leverages the unique biology of EBV T cells and has the capability to treat a wide range of EBV-associated diseases, or other serious diseases through incorporation of engineered CARs (chimeric antigen receptors) or TCRs (T-cell receptors). Christine Jackman SOUTH SAN FRANCISCO, Calif.-- (BUSINESS WIRE)-- Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced FUJIFILM Diosynth Biotechnologies, a subsidiary of FUJIFILM Fujifilm is currently accelerating business growth of Life Sciences field and continues to aggressively invest in both capital and technology in its bio CDMO business, said Teiichi Goto, president and chief executive officer, representative director, FUJIFILM Corporation. We also look forward to adding the facility to FUJIFILM Diosynth Biotechnologies existing global footprint and to bolster the expansion of our advanced therapies CDMO business.. View source version on businesswire.com: https://www.businesswire.com/news/home/20220401005459/en/, INVESTORS & MEDIA: Atara has retained a talented Technical Operations team who will continue to manage external manufacturing partnerships, manufacturing process science & development, quality assurance, supply chain, and logistics. "We are thrilled that through this acquisition we will add approximately 140 talented staff from Atara's cell therapy manufacturing facility to the FUJIFILM Diosynth . Information for With our lead program in Phase 3 clinical development and currently under review to support registration in Europe, Atara is the most advanced allogeneic T-cell immunotherapy company and intends to rapidly deliver off-the-shelf treatments to patients with high unmet medical need. Investors United Kingdom Eric Hyllengren For the year ended March 31, 2021, the company had global revenues of $21 billion, at an exchange rate of 106 yen to the dollar. Evercore Group LLC is acting as strategic advisor to Atara and Gibson Dunn & Crutcher LLP is acting as its legal counsel. Mitsubishi Corporation is a 20% shareholder of FUJIFILM Diosynth Biotechnologies UK, Research Triangle Park, North Carolina, Watertown, Massachusetts and College Station, Texas sites. HCRx is a leading royalty acquisition company focused on commercial or near-commercial stage biopharmaceutical products. The facility is the newest addition to FUJIFILM Diosynth Biotechnologies global portfolio of manufacturing sites which include facilities in College Station, Texas, USA, Research Triangle Park, North Carolina, USA, Teesside, UK, and Hillerd, Denmark. The upfront consideration, along with the reduction in operating expenses, in addition to Ataras existing cash, cash equivalents and short-term investments is expected to fund Ataras planned operations into Q4 2023, beyond the anticipated completion of the randomized, placebo-controlled Phase 2 study of ATA188, the Companys investigational off-the-shelf T-cell candidate that has the potential to reverse disability in progressive multiple sclerosis. Atara will retain its expertise, staff, and capabilities in manufacturing process science to continue to innovate in initial manufacturing and scale up for allogeneic cell therapies. TOKYO - FUJIFILM Corporation (President and CEO, Representative Director: Teiichi Goto) today announced that it has completed the acquisition of a dedicated cell therapy manufacturing facility from Atara Biotherapeutics, Inc. (Nasdaq: ATRA) for USD 100 million. With the new sites talent, strategic location on the West Coast, and potential for future capacity growth, we are confident that we will help our partners deliver T cell and CAR-T therapies to offer patients hope.. THOUSAND OAKS, Calif., December 20, 2022 -- ( BUSINESS WIRE )-- Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus. 805-395-9669 +1 919 337 4400, Belasis Avenue Furthermore, in order to expand the business in the most advanced biopharmaceutical fields, FUJIFILM Diosynth Biotechnologies joined Landmark Bio, the industry-academia research and development consortium,to explore the application of genetically modified cell therapies. TOKYO - FUJIFILM Corporation (President and CEO, Representative Director: Teiichi Goto) today announced that it has entered into an agreement to acquire a cell therapy manufacturing facility from Atara Biotherapeutics, Inc. (Nasdaq: ATRA) for USD 100 million. Fujifilm Completes Acquisition of a Dedicated Cell Therapy Manufacturing Facility from Atara Biotherapeutics, Inc. Press release 2023-04-19, Press release 2022-11-15, Press release 2022-10-27, In Person Lunch & Learn | Process Characterization, Paveway PLUS Microbial Expression Platform, FUJIFILM Diosynth Biotechnologies and RoosterBio Announce Collaboration to enable GMP Manufacturing of Cell and Exosome Therapies. Actively contributed and participated in the acquisition of Atara Biotherapeutics. Atara will also retain a talented technical operations team to manage external manufacturing, quality, logistics and supply. Upon closing, the upfront consideration, along with the reduction in operating expenses, in addition to Ataras existing cash, cash equivalents and short-term investments is expected to fund Ataras planned operations into Q4 2023, beyond the anticipated completion of the randomized, placebo-controlled Phase 2 study of ATA188, the Companys investigational off-the-shelf T-cell candidate that has the potential to reverse disability in progressive multiple sclerosis. FUJIFILM Diosynth Biotechnologies has over thirty years of experience in the development and manufacturing of recombinant proteins, vaccines, monoclonal antibodies, among other large molecules, viral products and medical countermeasures expressed in a wide array of microbial, mammalian, and host/virus systems. Our platform leverages the unique biology of EBV T cells and has the capability to treat a wide range of EBV-associated diseases, or other serious diseases through incorporation of engineered CARs (chimeric antigen receptors) or TCRs (T-cell receptors). ATOM is a 90,000 ft cutting edge T-cell therapy manufacturing facility fully qualified to support clinical and commercial production and designed with the flexibility to expand to support various production requirements and capacities. 805-395-9669 Located in Thousand Oaks, California, the facility is readily expandable with the flexibility to produce both clinical and commercial cell therapies including allogeneic T-cell and CAR T immunotherapies. We are incredibly proud of our world-class ATOM staff and the facility and believe that this strategic partnership will meet our long-term manufacturing needs. 805-395-9669 We believe that now is the right time for a strategic relationship with FUJIFILM Diosynth Biotechnologies to give us access to the expert manufacturing capability Atara will require, when needed. For more information you can read our Privacy Policy. December 20, 2022 Atara Biotherapeutics Announces $31 Million Royalty Interest Financing Agreement with HealthCare Royalty READ MORE December 19, 2022 Atara Biotherapeutics' Ebvallo (tabelecleucel) Receives European Commission Approval as First Ever Therapy for Adults and Children with EBV+ PTLD READ MORE MORE NEWS Dig deeper. We will now confidently further focus our capital resources on development and commercialization of our pipeline of first-in-kind therapeutics for severe diseases.. Because such statements deal with future events and are based on Ataras current expectations, they are subject to various risks and uncertainties and actual results, performance or achievements of Atara could differ materially from those described in or implied by the statements in this press release. In connection with this announcement, Atara will host a webcast and conference call today at 4pm PST / 7pm EST. Cookies are important to the proper functioning of a site. Following completion of the transaction, FDB, a leading contract development and manufacturing organization (CDMO) in advanced therapies, will provide Atara with access to the flexible capacity and specific capability needed to manufacture clinical and commercial-stage allogeneic cell therapies for its maturing and promising pipeline, including tabelecleucel (tab-cel), under regulatory review in Europe for EBV+ PTLD, ATA188 for multiple sclerosis, and allogeneic CAR T therapies, ATA3271 and ATA3219. 805-395-9669 Its proprietary core technologies contribute to the various fields including healthcare, highly functional materials, document solutions and imaging products. The Senior Engineer, MSAT will primarily be responsible for providing process technical support and subject matter expertise for late stage and commercial products. 2023 Atara Biotherapeutics, Inc. All rights reserved. reserved. For example, forward-looking statements include statements regarding: the development, timing, progress and prospects of Ataras product candidates and regulatory filings, Ataras sale of its manufacturing facility to FUJIFILM Diosynth Biotechnologies (FDB), the potential benefits of such transaction to Atara, including the potential financial benefits to Atara, the supply agreement between the parties and the duration and benefits thereof, FDBs ability to perform under the supply agreement and meet Ataras requirements, FDBs plans for the manufacturing facility, including the expansion thereof, Ataras ability to drive innovation, Ataras ability to retain its staff and capabilities, and the sufficiency of Ataras cash, cash equivalents, short-term investments to fund its planned operations. In 2015, Atara entered into a license agreement with the Memorial Sloan Kettering Cancer Center for development, manufacturing, and more. Because such statements deal with future events and are based on Ataras current expectations, they are subject to various risks and uncertainties and actual results, performance or achievements of Atara could differ materially from those described in or implied by the statements in this press release. About FUJIFILM Corporation . Eric Hyllengren Strength, Multiple . Klicken Sie auf Alle ablehnen, wenn Sie nicht mchten, dass wir und unsere Partner Cookies und personenbezogene Daten fr diese zustzlichen Zwecke verwenden. At closing, Fujifilm plans to offer positions to approximately 140 current highly-skilled manufacturing and quality staff at the site. The collective expertise of the team will further support our efforts as a world-class CDMO, added Martin Meeson, chief executive officer, FUJIFILM Diosynth Biotechnologies. The agreement is expected to reduce Ataras planned operating expenses over the multiyear period. Except as otherwise required by law, Atara disclaims any intention or obligation to update or revise any forward-looking statements, which speak only as of the date hereof, whether as a result of new information, future events or circumstances or otherwise. FUJIFILM Diosynth Biotechnologies, a subsidiary of FUJIFILM Corporation, is a world-leading contract development and manufacturing organization (CDMO) with experience in the development and manufacture of biologics, vaccines and advanced therapies. Atara will also retain a talented technical operations team to manage external manufacturing, quality, logistics and supply. FUJIFILM Corporation has invested over USD 5.5 billion to grow the Bio CDMO business unit in order to provide our customers with long-term support across a full-range of modalities, and manufacturing scales, said Takatoshi Ishikawa, senior executive vice president, general manager Bio CDMO Division, FUJIFILM Corporation. In its pursuit to establish itself as a comprehensive healthcare company covering prevention, treatment and diagnosis, FUJIFILM Corporation has made multiple strategic acquisitions over recent years to expand and diversify its healthcare portfolio. Studies, Expanded We believe that now is the right time for a strategic relationship with FDB to provide us with expert manufacturing capabilities, as needed. SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Sclerosis, Clinical achapman@atarabio.com, Atara SOUTH SAN FRANCISCO, Calif., April 04, 2022--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic EBV T-cell platform to develop . +44 1642 363511, 2430 Conejo Spectrum Street For more information, please visit: https://www.fujifilmholdings.com. christine.jackman@fujifilm.com With our lead program in Phase 3 clinical development and currently under review to support registration in Europe, Atara is the most advanced allogeneic T-cell immunotherapy company and intends to rapidly deliver off-the-shelf treatments to patients with high unmet medical need. The closing of the transaction, subject to expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act and other customary closing conditions, is expected to occur in April 2022. Fujifilm is committed to responsible environmental stewardship and good corporate citizenship. Sign up today for your free Reader Account. QIMR Berghofer In 2015, we obtained an exclusive license to develop and commercialize immunotherapies utilizing technology developed by Dr. Rajiv Khanna. The Engineering MSAT team supports the technical activities associated with T-cell manufacturing across the Atara manufacturing network. Eric Hyllengren For example, forward-looking statements include statements regarding: the development, timing, progress and prospects of Ataras product candidates and regulatory filings, Ataras proposed sale of its ATOM manufacturing facility to FUJIFILM Diosynth Biotechnologies (FDB), the parties ability to consummate such transaction, including the timing thereof, the potential benefits of such transaction to Atara, including the potential financial benefits to Atara, the proposed supply agreement between the parties and the duration and benefits thereof, FDBs ability to perform under the proposed supply agreement and meet Ataras requirements, FDBs potential plans for ATOM, including the expansion thereof, Ataras ability to drive innovation, Ataras ability to retain its staff and capabilities, and the sufficiency of Ataras cash, cash equivalents, short-term investments to fund its planned operations. 2023 Atara Biotherapeutics, Inc. All rights Our investigational T-cell therapies target difficult-to-treat Epstein-Barr virus (EBV)-driven conditions, including certain cancers and multiple sclerosis, as well as a wide range of non-EBV-associated diseases. With our lead program in Phase 3 clinical development and currently under review to support registration in Europe, Atara is the most advanced allogeneic T-cell immunotherapy company and intends to rapidly deliver off-the-shelf treatments to patients with high unmet medical need. (Business Wire) Atara Biotherapeutics, Inc. develops therapies for patients with solid tumors, hematologic cancers, and autoimmune diseases in the United States. Atara retains the recently established Thousand Oaks-based Atara Research Center (ARC), which is fully operational and will house Ataras Pre-Clinical, Translational Sciences, Manufacturing Process Sciences, and Analytical Development teams to further drive innovation by leveraging the Companys unique and differentiated allogeneic cell therapy platform. Located in Thousand Oaks, California, the facility is readily expandable with the flexibility to produce both clinical and commercial cell . ehyllengren@atarabio.com It will be operated as part of FUJIFILM Diosynth Biotechnologies' global network . Ataras Thousand Oaks-based Atara Research Center (ARC) now houses Ataras Pre-Clinical, Translational Sciences, Manufacturing Process Sciences, and Analytical Development teams to further drive innovation by leveraging the Companys unique and differentiated allogeneic cell therapy platform. The 90,000 sq. 805-456-4772 Thousand Oaks, CA 91320 TOKYO, Jan. 26, 2022 (GLOBE NEWSWIRE) -- FUJIFILM Corporation (President and CEO, Representative Director: Teiichi Goto) today announced that it has entered into an agreement to acquire a cell therapy manufacturing facility from Atara Biotherapeutics, Inc. (Nasdaq: ATRA) for USD 100 million. Fujifilm Expands its Advanced Therapies CDMO Business with the Acquisition of a Dedicated Cell Therapy Manufacturing Facility from Atara Biotherapeutics, Inc. TOKYO - FUJIFILM Corporation (President and CEO, Representative Director: Teiichi Goto) today announced that it has entered into an agreement to acquire a cell therapy manufacturing . Atara Biotherapeutics, Inc. (@Atarabio) is a pioneer in T-cell immunotherapy leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with serious diseases including solid tumors, hematologic cancers and autoimmune disease. About FUJIFILM Corporation These products and services are based on its extensive portfolio of chemical, mechanical, optical, electronic and imaging technologies. Mitsubishi Corporation is a 20% shareholder of FUJIFILM Diosynth Biotechnologies UK, Research Triangle Park, North Carolina, Watertown, Massachusetts and College Station, Texas sites. Atara is applying this one platform, which does not require TCR or HLA gene editing, to create a robust pipeline including: tab-cel in Phase 3 development for Epstein-Barr virus-driven post-transplant lymphoproliferative disease (EBV+ PTLD) and other EBV-driven diseases; ATA188, a T-cell immunotherapy targeting EBV antigens as a potential treatment for multiple sclerosis; and multiple next-generation chimeric antigen receptor T-cell (CAR-T) immunotherapies for both solid tumors and hematologic malignancies. The 90,000 sq. To be the leading and most trusted global Contract Development and Manufacturing Organization in the biopharmaceutical industry. About Atara Biotherapeutics, Inc. Atara Biotherapeutics, Inc. is a pioneer in T-cell immunotherapy leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with serious diseases including solid tumors, hematologic cancers and autoimmune disease. To improve your experience, we use cookies to remember log-in details and provide secure log-in, collect statistics to optimize site functionality and deliver content tailored to your interest.By continuing to use this site you are giving us your consent to do this.
Jonathan Blue Net Worth,
How To Calibrate Gp 300 Infrared Thermometer,
Usher Vegas Tickets 2022,
Articles A
